AbbVie struck a partnership with Disco Pharmaceuticals to develop programs across solid tumor targets, including antibody-drug conjugates and T cell engagers. The deal includes $40 million upfront and potential consideration of up to $2.54 billion, positioning Disco’s preclinical platform to accelerate into translational development. For biotech investors and pipeline strategists, the terms underscore continuing confidence in modular modality development for solid tumors, particularly where mechanism-driven payloads and immune engagement strategies can be paired to address resistance.